Last reviewed · How we verify
Lis-dexamphetamine
At a glance
| Generic name | Lis-dexamphetamine |
|---|---|
| Also known as | Vyvanse, LDX |
| Sponsor | Duke University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Day-time Response Variation of (Lis)Dexamphetamine
- Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study (NA)
- Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |